First Patient Dosed in Phase 1b Trial of Sitravatinib-Tislelizumab Combo for Advanced Solid Tumors

First Patient Dosed in Phase 1b Trial of Sitravatinib-Tislelizumab Combo for Advanced Solid Tumors
A Phase 1b clinical trial studying a combination of Mirati Therapeutics‘ small molecule inhibitor sitravatinib and BeiGene‘s immune checkpoint inhibitor tislelizumab has begun dosing patients. The open-label, multicenter trial (NCT03666143), expected to include 100 patients with advanced ovarian, lung, and kidney cancers, is being conducted in China and Australia. It is part of a collaboration between Mirati and

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *